Saturday, December 16, 2017
 
 
Company News: Page (1) of 1 - 12/07/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Asia-Pacific Asthma Therapeutics Markets 2017-2023 - Promising Product Pipeline and Launch of First-in-Class Molecules

By Globenewswire

Dublin, Dec. 07, 2017 (GLOBE NEWSWIRE) -- The "Asthma Therapeutics in Asia-Pacific Markets to 2023 - High Prevalence and Highly Priced Existing & Upcoming Biologics will Drive the Market" report has been added to Research and Markets' offering.



The report "Asthma Therapeutics in Asia-Pacific Markets to 2023 High Prevalence and Highly Priced Existing & Upcoming Biologics will Drive the Market" provides an introduction to asthma, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology and prognosis for patients. An analysis of current treatment algorithms and options is also included.

Asia-Pacific asthma therapeutics market is forecast to grow significantly over the forecast period, from $4.1 billion in 2016 to a projected value of $6 billion by 2023, at a compound annual growth rate (CAGR) of 5.4%.

Asthma treatment can be classed as either long-term control medication, aimed at controlling persistent asthma, or quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes inhaled corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and methylxanthines. In addition, long-acting beta-adrenoceptor agonists (LABA) can be used in combination with ICSs but not as monotherapies for moderate or severe persistent asthma. Currently, only two biologics Xolair (omalizumab) and Nucala (mepolizumab) are approved as add-on therapy for the treatment of allergic and severe refractory eosinophilic asthma in the Asia-Pacific region.

Page: 1


 
 
 
 
 
 
Computers
Engineering


 
 
 
 
 
 





Our Privacy Policy --- About The U.S. Daily News - Contact Us - Advertise With Us - Privacy Guidelines